Arcinova, a Quotient Sciences business, increases GC-MS/MS capabilities with new system
Arcinova, a Quotient Sciences business, increase GC-MS/MS capabilities with purchase of new Thermo Scientific TSQ Duo triple quadrupole.
Pharmaterials rebrands to Quotient Sciences
Quotient Sciences announces that it has completed the integration and rebrand of Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K.
Quotient Sciences and PPD Form Innovative Partnership to Accelerate Pediatric Drug Development
The collaboration simplifies contracting and delivery by offering clients a single solution for an entire pediatric program, with only one contract and one PPD point of contact. As a result of that structure, the number of handoffs is significantly reduced and the process is much more streamlined, eliminating the delays that often occur when moving from early dosing to later phases.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing Organization
Quotient Sciences announces it has acquired Pharmaterials, a CDMO based in Reading, UK. The acquisition strengthens and expands Quotient’s formulation and manufacturing services footprint and further supports the growth of Quotient’s Translational Pharmaceutics platform.
Quotient Sciences Launches as the New Global Identity for Quotient Clinical
Quotient Clinical, the drug development services organization, announces its renaming to Quotient Sciences (Quotient), following the acquisitions of Co-Formulate, QS Pharma and SeaView Research. This new identity signifies a global footprint and an extended range of services, and symbolizes the commitment to ensuring a consistent and high-quality experience for customers.
Quotient Sciences signs agreement with Nuformix to evaluate cocrystal formulations using Translational Pharmaceutics®
Quotient Sciences has signed an agreement with Nuformix Technologies Limited to evaluate the clinical performance of Nuformix’ lead pharmaceutical cocrystal, NXP001, which is based on a currently marketed treatment in the field of oncology supportive care.